Navigation Links
Cato T. Laurencin, M.D., Ph.D. to Join Osteotech Board of Directors

EATONTOWN, N.J., Sept. 25 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative medicine, announced today the appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors. Dr. Laurencin joined the Board of Directors effective September 24, 2008 and will serve on both the Audit and the Compensation Committees of the Board of Directors.

Kenneth P. Fallon, III, Chairman of the Board of Directors, commented, "We are excited about the addition of Dr. Laurencin to Osteotech's Board. Cato's experience and expertise as a nationally prominent orthopaedic surgeon will be of great assistance in helping the Board support the Company's new product development initiatives furthering its long-term growth objectives."

Since August 2008, Dr. Laurencin has been the Vice President for Health Affairs and the Dean of the School of Medicine at the University of Connecticut. Dr. Laurencin holds the Albert and Wilda Van Dusen Endowed Chair in Academic Medicine and is the Distinguished Professor of Orthopaedic Surgery at the University of Connecticut. Previously, Dr. Laurencin was the Lillian T. Pratt Distinguished Professor and the Chair of the Department of Orthopaedic Surgery at the University of Virginia and the Orthopaedic Surgeon-in-Chief at the University of Virginia Health System. Dr. Laurencin has been widely published in scholarly journals and holds more than twenty U.S. patents. He is also a member of the Institute of Medicine of the National Academy of Sciences.

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at .

SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
2. Cynthia Haines, M.D., Named Managing Editor of Physicians Briefing News Wire
3. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
4. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
5. BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
6. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
7. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
8. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group
9. David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence
10. Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
11. Barry Ginsberg, M.D., Ph.D. Elected to Biodels Board of Directors
Post Your Comments:
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... , November 26, 2015 ... device company specializing in imaging technologies, announced today that it ... as part of the Horizon 2020 European Union Framework Programme ... a large-scale clinical trial in breast cancer. , ... , --> --> The ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
Breaking Biology News(10 mins):